Polycystic Kidney Disease Autosomal Dominant

• CLINICAL_TRIALS trial_result · 2022-11-09
  Clinical Trial Update: A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients [Phase 2, Phase 3]

  Phase 2/3 trial of venglustat for autosomal dominant polycystic kidney disease was terminated; results were posted in 2022.

• CLINICAL_TRIALS trial_result · 2022-03-03
  Clinical Trial Update: Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD [Phase 4]

  Phase 4 trial investigating curcumin therapy for vascular dysfunction in Autosomal Dominant Polycystic Kidney Disease has completed with res…

• CLINICAL_TRIALS trial_result · 2022-03-03
  Clinical Trial Update: Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease [NA]

  A completed clinical trial investigating daily caloric restriction and intermittent fasting in adults with autosomal dominant polycystic kid…

• CLINICAL_TRIALS trial_result · 2021-09-05
  Clinical Trial Update: Feasibility Study of Metformin Therapy in ADPKD [Phase 2]

  Phase 2 feasibility study of metformin therapy in autosomal dominant polycystic kidney disease (ADPKD) completed with results posted in 2021…

• CLINICAL_TRIALS trial_result · 2019-11-27
  Clinical Trial Update: Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease [Phase 3]

  A Phase 3 long-term safety update for immediate-release tolvaptan in autosomal dominant polycystic kidney disease.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2019-01-14
  Clinical Trial Update: Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD [Phase 3]

  Phase 3 trial evaluating tolvaptan effects on renal plasma flow and glomerular filtration rate in autosomal dominant polycystic kidney disea…